Pacific Edge logo

PEB - Pacific Edge Share Price

NZD1.03 -0.0  -1.0%

Last Trade - 12:11am

Sector
Healthcare
Size
Mid Cap
Market Cap £396.5m
Enterprise Value £383.4m
Revenue £2.85m
Position in Universe 339th / 1832
Bullish
Bearish
Unlock PEB Revenue
Momentum
Relative Strength (%)
1m -2.04%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.90 4.98 3.21 3.40 3.82 4.37 10.9 28.6 +18.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2020, PacificEdge Ltd revenues increased 46% to NZ$3.3M. Net lossdecreased 24% to NZ$7.1M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflects Salesand Marketing decrease of 18% to NZ$3.4M (expense), Generaland Administration decrease of 13% to NZ$2.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for PEB
Graphical History

Revenue

PEB Revenue Unlock PEB Revenue

Net Income

PEB Net Income Unlock PEB Revenue

Normalised EPS

PEB Normalised EPS Unlock PEB Revenue

PE Ratio Range

PEB PE Ratio Range Unlock PEB Revenue

Dividend Yield Range

PEB Dividend Yield Range Unlock PEB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PEB EPS Forecasts Unlock PEB Revenue
Profile Summary

Pacific Edge Limited is a cancer diagnostics company. The Company develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The Company's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. It offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.

Directors
Last Annual March 31st, 2020
Last Interim September 30th, 2020
Incorporated February 27, 2001
Public Since February 12, 2003
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange New Zealand Stock Exchange
Shares in Issue 724,763,562
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PEB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PEB
Upcoming Events for PEB
Frequently Asked Questions for Pacific Edge
What is the Pacific Edge share price?

As of 12:11am, shares in Pacific Edge are trading at NZD1.03, giving the company a market capitalisation of £396.5m. This share price information is delayed by 15 minutes.

How has the Pacific Edge share price performed this year?

Shares in Pacific Edge are currently trading at NZD1.03 and the price has moved by 0.713k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacific Edge price has moved by 0.689k% over the past year.

What are the analyst and broker recommendations for Pacific Edge?

Of the analysts with advisory recommendations for Pacific Edge, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pacific Edge is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Pacific Edge next release its financial results?

Pacific Edge is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Pacific Edge dividend yield?

Pacific Edge does not currently pay a dividend.

Does Pacific Edge pay a dividend?

Pacific Edge does not currently pay a dividend.

When does Pacific Edge next pay dividends?

Pacific Edge does not currently pay a dividend.

How do I buy Pacific Edge shares?

To buy shares in Pacific Edge you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pacific Edge?

Shares in Pacific Edge are currently trading at NZD1.03, giving the company a market capitalisation of £396.5m.

Where are Pacific Edge shares listed? Where are Pacific Edge shares listed?

Here are the trading details for Pacific Edge:

Country of listing: New Zealand
Exchange: NZC
Ticker Symbol: PEB
What kind of share is Pacific Edge?

Based on an overall assessment of its quality, value and momentum, Pacific Edge is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pacific Edge share price forecast 2021?

Shares in Pacific Edge are currently priced at NZD1.03. At that level they are trading at 44.23% discount to the analyst consensus target price of 0.00.

Analysts covering Pacific Edge currently have a consensus Earnings Per Share (EPS) forecast of -0.018 for the next financial year.

How can I tell whether the Pacific Edge share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Edge. Over the past six months, the relative strength of its shares against the market has been 43.99%. At the current price of NZD1.03, shares in Pacific Edge are trading at 49.77% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pacific Edge PE Ratio?

We were not able to find PE ratio data for Pacific Edge.

Who are the key directors of Pacific Edge?

Pacific Edge's management team is headed by:

David Darling - CEO
Anatole Masfen - NED
Jackie Walker - CEX
Parry Guilford - CSO
Bryan Williams - NID
James Miller Suttie - SVP
Brent Pownall - VPR
David Levison - CEX
Chris Gallaher - NEC
Sarah Natalie Park - NID
Grant Edward Gibson - CFO
Jack Atchason - SVP
Tony Lough - VPR
Who are the major shareholders of Pacific Edge?

Here are the top five shareholders of Pacific Edge based on the size of their shareholding:

Harbour Asset Management Limited Investment Advisor
Percentage owned: 14.42% (104.9m shares)
BT Funds Management (New Zealand) Ltd. Investment Advisor
Percentage owned: 6.7% (48.8m shares)
AMP Capital Investors (New Zealand) Limited Investment Advisor
Percentage owned: 4.97% (36.1m shares)
K One W One Ltd. Corporation
Percentage owned: 4.28% (31.1m shares)
ANZ New Zealand Investments Limited Investment Advisor
Percentage owned: 3.87% (28.2m shares)
Similar to PEB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.